(188 days)
The product is intended to be used in a hospital or at home to obtain capillary blood samples from the fingertip for tests using small amounts of blood. The lancet is intended to be assembled with a lancing device, such that once the lancing device is launched, the needle of the lancet can prick the skin.
The Disposable Blood Lancets consists of a needle, a body and a cap. The models of the Disposable Blood Lancets are 18G; 21G; 23G; 26G; 28G; 30G; 32G; 33G. Disposable Blood Lancets are used to collect blood samples for hospital clinic test. It is sterilized by Irradiation and is a single-use product.
The provided document (K220387 510(k) summary for Disposable Blood Lancets) details acceptance criteria and the results of a study to demonstrate substantial equivalence to a predicate device, rather than a study proving significant improvement over human readers or standalone performance. The document focuses on performance testing against defined specifications for the device itself.
Here's a breakdown of the requested information based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
| No. | Testing Item | Acceptance Criteria (Specification) | Reported Device Performance (Result) |
|---|---|---|---|
| 01 | Appearance | Lancet should have the same color, no bubble, no flash, no slip. | Pass |
| 02 | Launch Length | The length of the needles in the Disposable Blood Lancets is different in different gauge. The general depth is 3.2mm. | Pass |
| 03 | Sharpness | Penetration force ≤1.00N. | Pass |
| 04 | Exterior | The connection between needle and needle body should be firm. | Pass |
| 05 | Cap twist | Cap twist should be smooth. | Pass |
| 06 | Initial bioburden | Initial bioburden of the device shall be less than 100CFU/g. | Pass |
| 07 | Sterile | The sterile blood lancet shall be sterile. | Pass |
In addition to these direct performance tests, biocompatibility, sterilization validation, and shelf life testing were also performed, with implied "Pass" results for substantial equivalence:
Biocompatibility Testing (Evaluated in accordance with ISO 10993-1:2018):
- Cytotoxic test (ISO 10993-5:2009)
- Skin sensitization test (ISO 10993-10:2010)
- Intracutaneous test (ISO 10993-10:2010)
- Acute systemic toxicity test (ISO 10993-11:2017)
- Hemolysis test (ISO 10993-4:2017)
- Pyrogen Test (USP <151>)
Sterilization and Shelf Life Testing:
- Irradiation sterilization validation per ISO 11173-1 and ISO 11173-3.
- Pyrogen testing per USP <151>.
- Simulated shipping per ASTM D4169.
- Stability study (including aging test) for a 5-year shelf life.
2. Sample Size Used for the Test Set and Data Provenance
The document does not explicitly state the specific sample sizes used for each individual test (e.g., how many lancets were tested for sharpness or appearance). It only reports "Pass" for each criterion.
The data provenance is from non-clinical testing performed by the manufacturer, Suzhou Kyuan Medical Apparatus Co., Ltd., in China. The study is a retrospective evaluation of the device's adherence to established performance and safety standards, typical for a 510(k) submission.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
This type of information is not applicable to the provided document. The "ground truth" for this device's performance is based on objective, quantifiable engineering and biological test standards (e.g., penetration force of 1.00N, bioburden < 100CFU/g, ISO and USP standards). Experts would be involved in designing and conducting these tests, but not in establishing a subjective "ground truth" through consensus, as might be the case for image interpretation AI.
4. Adjudication Method for the Test Set
Not applicable. Adjudication methods like "2+1" or "3+1" are typically used in studies involving subjective human interpretations (e.g., radiology reads) to establish a consensus ground truth. For the objective performance tests of a blood lancet, the results are typically binary (Pass/Fail) against a defined specification.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No, an MRMC comparative effectiveness study was not done. This type of study would compare human performance with and without AI assistance, which is irrelevant for a physical medical device like a blood lancet. The study focuses on the device's intrinsic physical and biological properties.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
Not applicable. This question pertains to AI/algorithm performance. The device is a physical blood lancet, not an algorithm. The "standalone performance" here refers to the device's ability to meet its specifications independently, which is what the non-clinical testing demonstrated.
7. The Type of Ground Truth Used
The "ground truth" for the Disposable Blood Lancets is established by:
- Engineering specifications: Quantifiable physical parameters (e.g., launch length, penetration force, connection firmness).
- Biological/Chemical standards: Bioburden levels, sterility test results, biocompatibility test results (cytotoxicity, sensitization, etc.) as defined by international standards (ISO, ASTM) and pharmacopeial standards (USP).
- Regulatory compliance: Adherence to predicate device characteristics and general safety/effectiveness principles as required for 510(k) clearance.
8. The Sample Size for the Training Set
Not applicable. The concept of a "training set" applies to machine learning or AI models. This submission is for a physical medical device, not an AI product. The assessment is based on physical and biological testing of the manufactured device.
9. How the Ground Truth for the Training Set Was Established
Not applicable. As a physical medical device, there is no "training set" or corresponding ground truth established in the context of machine learning. The device's design and manufacturing process are validated against established engineering and biological standards.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, with the word "ADMINISTRATION" underneath.
August 17, 2022
Suzhou Kyuan Medical Apparatus Co., Ltd. Shi Ye Manager Beigiao Town Suzhou, Jiangsu China
Re: K220387
Trade/Device Name: Disposable Blood Lancets Regulation Number: 21 CFR 878.4850 Regulation Name: Blood Lancets Regulatory Class: Class II Product Code: QRL, QRK Dated: July 18, 2022 Received: July 18, 2022
Dear Shi Ye:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
{1}------------------------------------------------
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
for Long Chen, Ph.D. Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K220387
Device Name Disposable Blood Lancets
Indications for Use (Describe)
The product is intended to be used in a hospital or at home to obtain capillary blood samples from the fingertip for tests using small amounts of blood. The lancet is intended to be assembled with a lancing device, such that once the lancing device is launched, the needle of the lancet can prick the skin.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
K220387 510(k) summary
l Submitter
Device submitter: Suzhou Kyuan Medical Apparatus Co., Ltd. Beiqiao Town, Suzhou City, P.R.China
Contact person: Shi Ye General Manager Phone: +86-512 65995113 Fax: +86-512 65412778 Email: shi.ye@medi-kyuan.com
510(k) number: K220387
Date: 08/17/2022
II Device
Trade Name of Device: Disposable Blood Lancets Common Name: Blood Lancets Regulation Number: 21 CFR 878.4850 Regulation Name: Single Use Only Blood Lancet without an Integral Sharps Injury Prevention Feature Regulatory Class: II Product code: QRK, QRL Review Panel: General & Plastic Surgery
III Predicate Devices
| Trade name: | Promisemed Blood Lancet (Used as predicted device |
|---|---|
| VeriFine Safety Lancet | |
| VeriFine Mini-Safety Lancet | |
| Common name: | Blood Lancets |
| Classification: | Class I, Lancet, Blood, 21CFR 878.4800 |
| Product Code: | FMK |
| Premarket Notification: | K192666 |
| Manufacturer: | Promisemed Hangzhou Meditech Co., Ltd. |
IV Device description
The Disposable Blood Lancets consists of a needle, a body and a cap. The models of the Disposable Blood Lancets are 18G; 21G; 23G; 26G; 28G; 30G; 32G; 33G.
{4}------------------------------------------------
Disposable Blood Lancets are used to collect blood samples for hospital clinic test. It is sterilized by Irradiation and is a single-use product.
V Indications for use
The product is intended to be used in a hospital or at home to obtain capillary blood samples from the fingertip for tests using small amounts of blood. The lancet is intended to be assembled with a lancing device, such that once the lancing device is launched, the needle of the lancet can prick the skin.
VI Comparison of technological characteristics with the predicate devices
The Disposable Blood Lancets have the same intended use, technology, design and performance specifications are either identical or substantially equivalent to existing legally marketed predicate devices. The differences between the Disposable Blood Lancets and predicate devices do not alter suitability of the proposed device for its intended use.
| Devicefeature | Subject Device 1(Disposable BloodLancets) | Predicate DeviceK192666(Promisemed BloodLancet) | Comment |
|---|---|---|---|
| Indicationsfor use | The product is intendedto be used in a hospitalor at home to obtaincapillary blood samplesfrom the fingertip for testsusing small amounts ofblood. The lancet isintended to beassembled with a lancingdevice, such that oncethe lancing device islaunched, the needle ofthe lancet can prick theskin. | It is intended for capillaryblood sampling. | SimilarComment1 |
| Productcode | QRK, QRL | FMK | DifferentComment1 |
| Reusedurability | Single use | Single use | Equivalent |
| Sterilization | Irradiation | Not available | Different |
| Devicefeature | Subject Device 1(Disposable BloodLancets) | Predicate DeviceK192666(Promisemed BloodLancet) | Comment |
| Comment2 | |||
| Principle ofOperation | The Disposable BloodLancets comprises astainless steel needleencapsulated with aplastic body and cap, thecap is twisted off toexpose the needle foruse. | The Promisemed BloodLancet comprises astainless steel needleencapsulated with a plasticbody and cap, the cap istwisted off to expose theneedle foruse. | Equivalent |
| Manufacturing | Stainless steel needle isfed into an injectionmolding machine to over-mold plastic material(polyethylene) forming abody and cap,encapsulating thestainless steel needles.Terminal sterilizationprocess is performed toensure sterility of anentire product. | For the Promisemed BloodLancet, stainless steelneedle is fed into aninjection molding machineto over-mold plasticmaterial (polyethylene)forming a body and cap,encapsulating thestainless steel needles.Terminal sterilizationprocess is performed toensure sterility of an entireproduct. | Equivalent |
| Model andSpecification | 18G; 21G; 23G; 26G;28G; 30G; 32G; 33G | BL-30 (30G)BL-28 (28G)(Information gathered fromPromisemed HangzhouMeditech Co., Ltd. officialwebsite) | DifferentComment3 |
| PenetrationDepth | $3.2mm\pm0.2$ | 3mm(Information gathered fromPromisemed HangzhouMeditech Co., Ltd. officialwebsite) | |
| Materials ofparts incontact withhumanbody | Lancet needle: stainlesssteel;Body and cap: PE | Lancet needle: stainlesssteel;Body and cap: PE | Equivalent |
{5}------------------------------------------------
{6}------------------------------------------------
Discussion:
Comment 1
The subject device and the predicate device have the same intended use, to puncture the skin to obtain drops of blood for diagnostic purposes. While the Disposable Blood Lancets have no sharp's prevention features and without the intended use of protecting the user from a needlestick injury. This difference does not affect the clinical safety of the subject device.
Comment 2
The sterilization method of predicate device is not available. However, the subject device was ensured sterility by sterilization validation. Therefore, the differences on sterilization do not raise new questions about safety and effectiveness.
Comment 3
Through comparative analysis, the model was more than as the predicated products, while the puncture depths are same. Different models are only different in the outer diameter of the needle, which allowed to choose to meet blood volume needs. Different needle specification will be selected by physician per patient's condition and this different were addressed by performance tests. This difference does not affect the basic design principle, usage, effectiveness and safety of the subject device. And no question is raised regarding to effectiveness and safety.
VII Summary of non-clinical testing
The following performance data were provided in support of the substantial equivalence determination.
| No | Testingitem | Specification | Result |
|---|---|---|---|
| 01 | Appearance | Lancet should have the same color, no bubble, noflash, no slip. | Pass |
| 02 | LaunchLength | The length of the needles in the Disposable BloodLancets is different in different gauge. The generaldepth is 3.2mm | Pass |
| 03 | Sharpness | Penetration force ≤1.00N. | Pass |
| 04 | Exterior | The connection between needle and needle bodyshould be firm. | Pass |
Performance Testing for Disposable Blood Lancets
{7}------------------------------------------------
| 05 | Cap twist should be smooth. | Pass | |
|---|---|---|---|
| 06 | Initialbioburden | Initial bioburden of the device shall be less than100CFU/g | Pass |
| 07 | Sterile | The sterile blood lancet shall be sterile | Pass |
Biocompatibility testing
Biocompatibility of the Disposable Blood Lancets were evaluated in accordance with ISO 10993-1:2018 for the body contact category. The following tests were performed, as recommended:
| Cytotoxic test | ISO 10993-5:2009 |
|---|---|
| Skin sensitization test | ISO 10993-10:2010 |
| Intracutaneous test | ISO 10993-10:2010 |
| Acute systemic toxicity test | ISO 10993-11:2017 |
| Hemolysis test | ISO 10993-4:2017 |
| Pyrogen Test | USP <151> |
Sterilization and shelf life testing
- Irradiation sterilization validation per ISO 11173-1 and ISO 11173-3. >
- A Pyrogen testing per USP <151>
- A Simulated shipping per ASTM D4169
- A The 5 years shelf life of the device is determined based on stability study which includes ageing test.
VIII Conclusion
The Disposable Blood Lancets are substantially equivalent to its predicate device (Promisemed Blood Lancet). The differences between the predicate and subject device do not raise any new or different questions of safety or effectiveness. The non-clinical testing demonstrates that the device is as safe, as effective and performs as well as the legally marketed device.
§ 878.4850 Blood lancets.
(a)
Single use only blood lancet with an integral sharps injury prevention feature —(1)Identification. A disposable blood lancet intended for a single use that is comprised of a single use blade attached to a solid, non-reusable base (including an integral sharps injury prevention feature) that is used to puncture the skin to obtain a drop of blood for diagnostic purposes. The integral sharps injury prevention feature allows the device to be used once and then renders it inoperable and incapable of further use.(2)
Classification. Class II (special controls). The special controls are:(i) The design characteristics of the device must ensure that the structure and material composition are consistent with the intended use and must include a sharps injury prevention feature.
(ii) Mechanical performance testing must demonstrate that the device will withstand forces encountered during use and that the integral sharps injury prevention feature will irreversibly disable the device after one use.
(iii) The device must be demonstrated to be biocompatible.
(iv) Sterility testing must demonstrate the sterility of any device component that breaches the skin (
e.g., blade).(v) Labeling must include:
(A) Detailed descriptions, with illustrations, of the proper use of the device and its sharps injury prevention feature.
(B) Handwashing instructions for the user before and after use of the device.
(C) Instructions on preparation (
e.g., cleaning, disinfection) of the skin to be pierced.(D) Instructions for the safe disposal of the device.
(E) Labeling must be appropriate for the intended use environment.
(
1 ) For those devices intended for health care settings, labeling must address the health care facility use of these devices, including how these lancets are to be used with personal protective equipment, such as gloves.(
2 ) For those devices intended for use in the home, labeling must be written so that it is understandable to lay users.(vi) Labeling must also include the following statements, prominently placed:
(A) “For use only on a single patient. Discard the entire device after use.”
(B) “Warning: Not intended for more than one use. Do not use on more than one patient. Improper use of blood lancets can increase the risk of inadvertent transmission of bloodborne pathogens, particularly in settings where multiple patients are tested.”
(b)
Single use only blood lancet without an integral sharps injury prevention feature —(1)Identification. A disposable blood lancet intended for a single use that is comprised of a single use blade attached to a solid, non-reusable base that is used to puncture the skin to obtain a drop of blood for diagnostic purposes.(2)
Classification. Class II (special controls). The special controls are:(i) The design characteristics of the device must ensure that the structure and material composition are consistent with the intended use and address the risk of sharp object injuries and bloodborne pathogen transmissions.
(ii) Mechanical performance testing must demonstrate that the device will withstand forces encountered during use.
(iii) The device must be demonstrated to be biocompatible.
(iv) Sterility testing must demonstrate the sterility of any device component that breaches the skin (
e.g., blade).(v) Labeling must include:
(A) Detailed descriptions, with illustrations, of the proper use of the device.
(B) Handwashing instructions for the user before and after use of the device.
(C) Instructions on preparation (
e.g., cleaning, disinfection) of the skin to be pierced.(D) Instructions for the safe disposal of the device.
(E) Labeling must be appropriate for the intended use environment.
(
1 ) For those devices intended for health care settings, labeling must address the health care facility use of these devices, including how these lancets are to be used with personal protective equipment, such as gloves.(
2 ) For those devices intended for use in the home, labeling must be written so that it is understandable to lay users.(vi) Labeling must also include the following statements, prominently placed:
(A) “For use only on a single patient. Discard the entire device after use.”
(B) “Warning: Not intended for more than one use. Do not use on more than one patient. Improper use of blood lancets can increase the risk of inadvertent transmission of bloodborne pathogens, particularly in settings where multiple patients are tested.”
(c)
Multiple use blood lancet for single patient use only —(1)Identification. A multiple use capable blood lancet intended for use on a single patient that is comprised of a single use blade attached to a solid, reusable base that is used to puncture the skin to obtain a drop of blood for diagnostic purposes.(2)
Classification. Class II (special controls). The special controls are:(i) The design characteristics of the device must ensure that:
(A) The lancet blade can be changed with every use, either manually or by triggering a blade storage unit to discard the used blade and reload an unused blade into the reusable base; and
(B) The structure and material composition are consistent with the intended use and address the risk of sharp object injuries and bloodborne pathogen transmissions and allow for validated cleaning and disinfection.
(ii) Mechanical performance testing must demonstrate that the device will withstand forces encountered during use.
(iii) The device must be demonstrated to be biocompatible.
(iv) Sterility testing must demonstrate the sterility of any device component that breaches the skin (
e.g., blade).(v) Validation testing must demonstrate that the cleaning and disinfection instructions are adequate to ensure that the reusable lancet base can be cleaned and low level disinfected.
(vi) Labeling must include:
(A) Detailed descriptions, with illustrations, of the proper use of the device.
(B) The Environmental Protection Agency (EPA) registered disinfectant's contact time for disinfectant use.
(C) Handwashing instructions for the user before and after use of the device.
(D) Instructions on preparation (
e.g., cleaning, disinfection) of the skin to be pierced.(E) Instructions on the cleaning and disinfection of the device.
(F) Instructions for the safe disposal of the device.
(G) Instructions for use must address the safe storage of the reusable blood lancet base between uses to minimize contamination or damage and the safe storage and disposal of the refill lancet blades.
(H) Labeling must be appropriate for the intended use environment.
(
1 ) For those devices intended for health care settings, labeling must address the health care facility use of these devices, including how these lancets are to be used with personal protective equipment, such as gloves.(
2 ) For those devices intended for use in the home, labeling must be written so that it is understandable to lay users.(vii) Labeling must also include the following statements, prominently placed:
(A) “For use only on a single patient. Disinfect reusable components according to manufacturer's instructions between each use.”
(B) “Used lancet blades must be safely discarded after a single use.”
(C) “Warning: Do not use on more than one patient. Improper use of blood lancets can increase the risk of inadvertent transmission of bloodborne pathogens, particularly in settings where multiple patients are tested. The cleaning and disinfection instructions for this device are intended only to reduce the risk of local use site infection; they cannot render this device safe for use for more than one patient.”
(d)
Multiple use blood lancet for multiple patient use —(1)Identification. A multiple use capable blood lancet intended for use on multiple patients that is comprised of a single use blade attached to a solid, reusable base that is used to puncture the skin to obtain a drop of blood for diagnostic purposes.(2)
Classification. Class III (premarket approval).(3)
Date PMA or notice of completion of a PDP is required: A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before May 22, 2024, for any multiple use blood lancet for multiple patient use described in paragraph (d)(1) of this section that was in commercial distribution before May 28, 1976, or that has, on or before May 22, 2024, been found to be substantially equivalent to a multiple use blood lancet for multiple patient use described in paragraph (d)(1) of this section that was in commercial distribution before May 28, 1976. Any other multiple use blood lancet for multiple patient use shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.